ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01870310
Recruitment Status : Unknown
Verified June 2013 by doc. MUDr. Miloš Táborský, CSc., FESC, MBA, University Hospital Olomouc.
Recruitment status was:  Recruiting
First Posted : June 6, 2013
Last Update Posted : June 6, 2013
Sponsor:
Information provided by (Responsible Party):
doc. MUDr. Miloš Táborský, CSc., FESC, MBA, University Hospital Olomouc

Brief Summary:
It is a randomized prospective controlled study evaluating the effect of transcatheter renal denervation on the clinical status of patients with chronic heart failure and its safety procedures. The working hypothesis of the study is that by performing transcatheter renal denervation in patients with chronic heart failure and severe left ventricular systolic dysfunction there will a resultant reduction in the renal sympathetic activation which in turn will reduce the number of hospitalizations and deaths from heart failure.

Condition or disease Intervention/treatment Phase
Heart Failure Procedure: Catheterised renal denervation Not Applicable

Detailed Description:

Chronic heart failure in the European countries occurs in 2-3% of the population with a significant increase in the higher age groups (1). Improved treatment of acute conditions (especially myocardial infarction) has resulted in more patients entering into the category of chronic heart failure. Chronic heart failure has a poor prognosis. Diagnosis and treatment are challenging both medically and economically. Half of the patients with systolic heart failure die within 4 years and more than 50% of patients with severe heart failure (NYHA functional class of IV) die within one year (1). The current treatments for heart failure are not only aimed at influencing the symptoms, but also preventing the progression of heart failure to reduce mortality.

Heart failure leads to the activation of compensatory mechanisms designed to restore adequate cardiac output. These mechanisms are initially beneficial, but their long-term activation leads to further progression of the pathological process and deterioration of cardiac function. One of the basic pathophysiological processes in heart failure is excessive activation of the sympathetic nervous system. This causes increased levels of circulating catecholamines which is proportional to the severity of the disease that is patients with the highest levels of norepinephrine have the worst prognosis. Beta-blocker therapy which is designed to inhibit activity of sympathetic nervous system causes milder symptoms of heart failure in patients by modifying disturbed hemodynamics and ultimately the clinical status. In recent years, the therapeutic efficacy of beta-blockers in chronic heart failure has been verified in a number of controlled clinical trials (2-5). These studies have confirmed that long-term treatment with beta-blocker therapy alleviates the symptoms of heart failure, improves the clinical condition of the patients and reduces mortality like ACE inhibitors.

High activity of renal sympathetic nerves in patients with chronic heart failure is an early predictor of increased mortality (6). The main pathophysiological basis of this finding is probably excessive sodium retention due to direct activation of sympathetic fibers innervating renal tubules (7). Recent experimental work on animals have shown that surgical renal denervation inhibits an increase in renal vascular resistance, prevents a decrease in renal blood flow (8), and also prevents changes in expression of angiotensin receptors in the kidney (8).

Surgical sympathectomy began to be used for the treatment of severe and malignant hypertension more than 50 years ago. But this was a rather complicated procedure, which was accompanied by a number of adverse effects (orthostatic hypotension and tachycardia, shortness of breath, bowel and sexual disorders]. Moreover it required a long hospitalization of 2-4 weeks and then required a recovery period of 1-2 months. However this intervention led to a rapid decrease in pressure and a higher survival rate after surgery in a large observational study(9).

In recent years a method has been developed in which destruction of renal sympathetic nerves that are present in the adventitia of renal arterial walls is done by catheterization (10). This procedure uses a catheter with a radiofrequency ablator at its tip (Symplicity, Ardian / Medtronic, USA), which is introduced through the femoral artery and then progressively introduced into the renal arteries. A randomized study has demonstrated that this procedure has a high degree of safety for the patients and a high rate of efficacy as well. In patients with resistant hypertension treated with transcatheter renal denervation there was a significant drop in blood pressure of 33/11 mmHg (p < 0.0001) that occurred after 6 months compared to a control group receiving unmodified pharmacological treatment (11).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.
Study Start Date : June 2012
Estimated Primary Completion Date : September 2013
Estimated Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
No Intervention: Standard medical therapy
Experimental: Renal denervation + standard medical therapy
Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
Procedure: Catheterised renal denervation
Other Name: Symplicity, Ardian / Medtronic, USA




Primary Outcome Measures :
  1. Change in serum NT-proBNP at 6 months and 1 year from baseline in both groups. [ Time Frame: 6 months and 1 year ]
    The level of NT-proBNP (N-terminal prohormone of Brain Natriuretic Peptide) is a reliable indicator of the severity of heart failure. Lowering levels will indicate improvement in the heart function.


Secondary Outcome Measures :
  1. Reduction in the number of hospitalizations and/or deaths due to cardiovascular causes. [ Time Frame: 1 year to 4 years ]

Other Outcome Measures:
  1. Significant Renal impairment and symptomatic hypotension. [ Time Frame: 6 months to 1 year ]
    Increase in serum creatinine of 2 times the baseline or decrease in estimated glomerular filtration according to MDRD (Modification of Diet in Renal Disease) by more than 50% from baseline will be used to assess renal function.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients over 18 years of age with chronic heart failure, ischemic and non-ischemic etiology.
  • NYHA (New York Heart Association) class II-IV.
  • LVEF (Left Ventricular Ejection Fraction) ≤ 35%.
  • Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, who were stable for at least four weeks without acute decompensated heart failure.
  • Prior to enrollment, patients must give informed consent.

Exclusion Criteria:

  • Patients with history of acute coronary syndrome or stroke within the last 6 months.
  • Significant valvular defects and/or planned cardiac surgery.
  • Systolic blood pressure <110 mmHg.
  • Advanced renal insufficiency (estimated GFR (Glomerular Filtration Rate) according to MDRD <30 ml/min/1.73 square meters).
  • Unsuitable anatomy of renal arteries (presence of significant renal stenosis, renal artery narrower than 4 mm).
  • Patients who underwent renal angioplasty or stent placement into the renal artery in the past.
  • Severe coagulation disorders.
  • Pregnancy or lactation.
  • Refusal of the patient.
  • Other diseases limiting prognosis of the patient to less than 2 years.
  • Other reasons which in the opinion of the attending physician would preclude the individual from participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870310


Contacts
Contact: Dagmar Strnkova, Mgr. +420 588 443 716 dagmarstrnkova@seznam.cz
Contact: Albert Louis, MUDr. +420 588 443 238 albertlouis3@gmail.com

Locations
Czech Republic
University Hospital, Olomouc Recruiting
Olomouc, Czech Republic, 775 20
Contact: Miloš Táborský, doc., MUDr., CSc., FESC, MBA    +420 588 443 201    milos.taborsky@fnol.cz   
Contact: Albert Louis, MUDr.    +420 588 443 238    albertlouis3@gmail.com   
Principal Investigator: Miloš Táborský, doc., MUDr., CSc., FESC, MBA         
Sub-Investigator: Albert Louis, MUDr.         
Sponsors and Collaborators
University Hospital Olomouc
Investigators
Principal Investigator: Miloš Táborský, doc., MUDr., CSc., FESC, MBA Head of Department of First Clinic of Internal Medicine - Cardiology, University Hospital, Olomouc.

Publications:
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17. Review. Erratum in: Eur Heart J. 2010 Apr;12(4):416. Dosage error in article text. Eur Heart J. 2010 Mar;31(5):624. Dosage error in article text.

Responsible Party: doc. MUDr. Miloš Táborský, CSc., FESC, MBA, Head of Department of First Clinic of Internal Medicine - Cardiology, University Hospital Olomouc
ClinicalTrials.gov Identifier: NCT01870310     History of Changes
Other Study ID Numbers: OLOMOUC 1
First Posted: June 6, 2013    Key Record Dates
Last Update Posted: June 6, 2013
Last Verified: June 2013

Keywords provided by doc. MUDr. Miloš Táborský, CSc., FESC, MBA, University Hospital Olomouc:
Heart failure
Renal denervation

Additional relevant MeSH terms:
Heart Failure
Ventricular Dysfunction
Ventricular Dysfunction, Left
Heart Diseases
Cardiovascular Diseases